Needham Maintains Buy on Hims & Hers Health, Raises Price Target to $35

Benzinga Newsdesk www.benzinga.com Positive 72.8%

Neg 0% Neu 0% Pos 72.8%

Needham analyst Ryan MacDonald maintains Hims & Hers Health (NYSE:HIMS) with a Buy and raises the price target from $30 to $35.